Genelux Corporation (NASDAQ:GNLX) Financings

Genelux Corporation

Financings

RaiseDate
At-the-market programme of common stock
Tranche closed: US$5.1M raised
Use of proceeds: Together with existing cash, expected to fund operations into the first quarter of 2027
Nov 16, 2026
Public offering of common stock
Announced: about US$20M · US$3 a share · Lucid Capital Markets
Dealers: Lucid Capital Markets (lead)
Use of proceeds: General corporate purposes, possibly including research and development, clinical trial expenses, capital expenditures and working capital
Jan 8, 2026
Public offering of common stock
Closed: US$10.5M raised · US$3.5 a share · Titan Partners Group, a division of American Capital Partners
Dealers: Titan Partners Group, a division of American Capital Partners (lead)
Use of proceeds: Working capital and general corporate purposes, including continued clinical development of Olvi-Vec
Mar 28, 2025

Read by 6ix AI from the company's releases